Brought to you by 
Ansan and Discovery Laboratories merge
13 Jul 1999
Executive Summary
Publicly traded Ansan Pharmaceuticals (anticancer therapeutics) will merge with Discovery Laboratories (private; mostly respiratory products). Post-merger, Discovery will own 90% of the new firm, which will be public.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ansan and Discovery Laboratories merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice